BEGIN:VCALENDAR METHOD:PUBLISH VERSION:2.0 CALSCALE:GREGORIAN PRODID:-//NONSGML WPForms//NONSGML Sugar Calendar Feeds v3.9.0//EN X-WR-CALNAME:Vaccination in the Immunocompromised Patient X-WR-CALDESC:Immunisation Coalition X-WR-TIMEZONE:Australia/Melbourne BEGIN:VTIMEZONE TZID:Australia/Melbourne BEGIN:DAYLIGHT TZOFFSETFROM:+1000 TZOFFSETTO:+1100 DTSTART:20251004T160000 TZNAME:AEDT END:DAYLIGHT END:VTIMEZONE BEGIN:VTIMEZONE TZID:Australia/Melbourne BEGIN:DAYLIGHT TZOFFSETFROM:+1000 TZOFFSETTO:+1100 DTSTART:20251004T160000 TZNAME:AEDT END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT SUMMARY:Vaccination in the Immunocompromised Patient DESCRIPTION:This comprehensive\, evidence-based course will give you the confidence to safely vaccinate immunocompromised individuals. Click ‘ Take this Course’ to get access and strengthen your clinical expertise today.\n\n\n\n\nRegister or Login\n\n\n\nKeep Reading \n\n\n\n\n\n\n\n\ n\n\n\nAbout\n\n\n\nVaccination is a cornerstone of public health\, offe ring crucial protection against preventable infectious diseases. For imm unocompromised individuals\, whose immune systems are weakened due to un derlying conditions or medical treatments\, the importance of vaccinatio n becomes even more pronounced.\n\n\n\nThe aim of this program is to pro vide a comprehensive overview of vaccination in the context of immunocom promised states\, exploring both the science and clinical application of immunisation and to provide guidance for healthcare professions treatin g and managing this high-risk group of individuals.\n\n\n\nWe will begin by reviewing the importance of vaccination\, particularly in reducing t he heightened risk of infection\, exacerbation of underlying diseases\, treatment\, and morbidity and mortality. We will look at the basic mecha nisms and types of vaccines and provide guidance and recommendations for vaccination in immunocompromised patients.\n\n\n\nSpecial attention wil l be given to the timing of vaccinations and the need for booster doses to ensure sustained immunity. We’ll delve into various immunocompromis ed states—ranging from primary immune deficiencies to conditions such as diabetes\, HIV/AIDS\, and treatments like chemotherapy and cellular t herapy—to understand how these factors influence vaccination approache s.\n\n\n\nThrough this module\, you will gain familiarity with current n ational guidelines and recommendations from authorities such as the TGA\ , ATAGI\, NIP\, and AIH\, focusing on appropriate vaccine selection and scheduling for immunocompromised individuals. We'll also address how vac cine efficacy may differ in this group\, alongside contraindications rel ated to specific vaccines\, including live attenuated formulations.\n\n\ n\nLastly\, we’ll explore safety considerations\, potential side effec ts\, and the importance of post-vaccination monitoring.\n\n\n\nBy the en d of this module\, you will be equipped with the knowledge and tools nee ded to make informed\, evidence-based vaccination decisions for immunoco mpromised patients\, to optimise protection for the patients and minimis e risk caused by infectious diseases outlined in this program.\n\n\n\nLe arning Objectives\n\n\n\n\nReview the importance of vaccination: increas ed risk of infection\, exacerbation of the underlying disease\, required intensive treatment\, hospitalisation and death\n\n\n\n\n\nReview the b asic mechanisms and types of vaccines\n\n\n\n\n\nReview the importance o f vaccination timing and the need for boosters\n\n\n\n\n\nUnderstand Imm unocompromised states including common conditions and treatments\, e.g.\ , primary immune deficiencies\, chemotherapy\, post cellular therapy\, a nd chronic medical conditions such as solid tumour cancers\, diabetes an d HIV/AIDS\n\n\n\n\n\nVaccination recommendations: identify which vaccin es are recommended for immunocompromised patients (TGA\, ATAGI\, NIP\, A IH) and the appropriate timing for vaccination\n\n\n\n\n\nAssessing vacc ine efficacy: explain how the immune response to vaccines may differ in immunocompromised individuals compared to the general population\n\n\n\n \n\nContraindications: highlight common contraindications and for specif ic vaccines in immunocompromised individuals\, including inactivated and live attenuated vaccines\n\n\n\n\n\nSafety and monitoring: discuss safe ty considerations and potential side effects of vaccinations in this pop ulation\, as well as the importance of monitoring after vaccination\n\n\ n\n\n\nReview patient cases and put the learnings into practice\n\n\n\n\ nFaculty Reviewers\n\n\n\n\nProfessor Paul Griffin▼\nAn Infectious Dis eases Physician and Clinical Microbiologist\, Professor Paul Griffin was appointed as the Director of Infectious Diseases at Mater Health Servic es in 2013\, and most recently\, to his conjoint role as Head of the Mat er Clinical Unit for the University of Queensland School of Medicine.&nb sp\;\n\n\n\nPaul is an accomplished clinical trial investigator\, having fulfilled the role of Principal Investigator in over 150 clinical trial s\, particularly in Infectious Diseases including 8 COVID-19 vaccines.&n bsp\;\n\n\n\nDespite an already demanding role at the Mater\, Paul conti nues as a member of the AMA Queensland Council 2023-2024\, and as board member and scientific advisory board member of the Immunisation Coalitio n\, with active interest in vaccine education and advocacy\, becoming a trusted media authority and spokesperson across the nation during the CO VID-19 pandemic.\n\n\n\n\nAngela Newbound▼\nAn Immunisation Education Consultant based in South Australia and a member of the Immunisation Coa lition.\n\n\n\nAngela has been involved in immunisation program delivery in South Australia \;for over 24 years\, originally as an immunisat ion provider\, and then \;in program coordinator roles within the Di visions of General Practice\, SA Health Immunisation Section\, the Medic are Local Network and the Primary Health Network until December 2024 in which she \;provided clinical advice\, support and education to a wi de range of immunisation providers.\n\n\n\n\nRebecca James▼\nRebecca i s a clinical nurse in Cancer Outpatients at the Royal Adelaide Hospital (RAH) and has worked across cancer wards\, radiotherapy\, cancer day cen tre and clinics over the last 12 years.\n\n\n\nRebecca graduated from th e University of South Australia in 2011 and then completed a Graduate Ce rtificate in Cancer Nursing with University of Tasmania and a Certificat e in Palliative Care from the University of South Australia.\n\n\n\nRebe cca works with a small team of highly skilled cancer nurses assisting in the management of cancer side effects\, supportive therapies\, chemothe rapy and post stem cell transplant vaccinations. \n\n\n\nShe has an inte rest in the vaccination process to help a unique group of patients acces s their vaccinations in a timely and safe manner\, either in the communi ty or at the RAH.\n\n\n\n\n\nPrice: $199\n\n\n\n\nTake Course URL;VALUE=URI:https://immunisationcoalition.org.au/events/vaccination-in -the-immunocompromised-patient/ UID:urn:uuid:8a961681-433a-4541-92c3-ca26aabce8c1 STATUS:CONFIRMED ORGANIZER: DTSTAMP:20260609T123943Z DTSTART;TZID=Australia/Melbourne:20251015T000000 DTEND;TZID=Australia/Melbourne:20251015T000000 END:VEVENT END:VCALENDAR